Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of Evogene stock opened at $1.42 on Friday. The company’s fifty day moving average price is $1.58 and its two-hundred day moving average price is $2.24. Evogene has a 52-week low of $1.20 and a 52-week high of $10.40. The firm has a market capitalization of $7.60 million, a PE ratio of -0.32 and a beta of 1.29.

Evogene (NASDAQ:EVGN) last posted its earnings results on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share for the quarter. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%.

Institutional Investors Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.